Relugolix is a Gonadotropin Releasing Hormone Receptor Antagonist. The mechanism of action of relugolix is as a Gonadotropin Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Relugolix
Drug Overview
What is Relugolix?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Relugolix is a chemical or natural-source material identified by this name. Its exact composition, grade, and intended role should be confirmed from the applicable product or technical documentation. A toxicological assessment should use reliable information for the specific material and avoid assuming properties that are not established by the available evidence.
A PDE or ADE sets a health-based limit on daily exposure to Relugolix from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
The assessment considers how Relugolix may be handled during relevant activities such as dispensing, charging, transfer, sampling, equipment maintenance, and cleaning. Exposure potential depends on the process, material form, containment, and work practices. Considering the actual tasks helps connect the toxicological evaluation with practical controls and identifies where additional exposure information may be useful.
Formulation and cleaning steps can involve different handling conditions and potential exposure pathways for Relugolix. The assessment should consider the material form, process design, containment, and tasks performed, using available evidence to characterize plausible exposure. These details help determine whether additional controls or route-specific evaluation may be needed, while keeping conclusions tied to the actual manufacturing context.
An exposure limit may still be assessed for a chemical that is not a marketed drug when there is a defined need to manage occupational exposure or cross-contamination. The approach depends on the available toxicological information and may consider related compounds or structure-based evidence where scientifically justified. Assumptions and limitations should be documented rather than presented as established facts.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Relugolix in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
The assessment may consider repeat-dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, and pharmacological activity where relevant data are available. The critical endpoint is selected by evaluating the reliability and relevance of the evidence. Data gaps and assumptions should be documented so the basis for the health-based exposure limit is transparent.
Not automatically. A PDE or ADE is derived for a defined assessment context and route, often oral exposure when evaluating residual carryover into another product. Applying the value to inhalation or dermal exposure may require additional scientific justification. The report should clearly state its scope, route assumptions, and any limitations relevant to use.
A PDE or ADE addresses an acceptable daily exposure in a defined context, commonly to support assessment of residual carryover between products. An OEL addresses exposure in the workplace, often focusing on inhalation over a specified period. These values serve different purposes and should not be treated as interchangeable without a scientific justification.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Relugolix to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
